Search NLS News

Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad before settling in Sweden. While up until recently, most of Iris Öhrn’s goals were professional, now she is seeking to have more of an impact […]

Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. An investigational cell […]

The DDD Platform spin-out company has secured investments from Sciety Venture Partners and Linc AB, in a venture capital round led by Sciety. The investment company Linc AB participated in the share issue with SEK 20 million. “We would like to thank Sciety and all those who have participated in this successful issue for the […]

XNK Therapeutics has announced the appointment of Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Hovstadius will be a member of the company’s management team.  Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor. “Peter has a solid background in oncology and clinical trials development from […]

BerGenBio has announced the formation of a scientific advisory board consisting of four non-small cell lung cancer (NSCLC) experts from top oncology centers around the globe to enhance the development of bemcentinib for the treatment of NSCLC patients with STK11 mutations. “We are very proud and honored to have assembled a group of leading international […]

SynAct Pharma has announced that its Chief Financial Officer, Patrik Renblad has resigned and will move to a new assignment outside of the company. He will leave SynAct by the end of July, 2023, at the latest. Patrik Renblad joined SynAct in 2021 and has during his tenure been instrumental in preparing the company for […]

Thomas (Tom) Gibbs is appointed as Executive Vice President and Head of Lundbeck in the United States. Tom will be based in Lundbeck’s U.S. head office in Chicago, Illinois, and assume the role no later than end of February 2023. “We look forward to having Tom join Lundbeck and the Executive Management team. He brings […]

The company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of […]

Lundbeck recently joined the world’s largest federated health data network EHDEN. Despite our best efforts to provide optimal healthcare to patients, there is still room for improvement across many disease areas. Randomized clinical trials (RCT) are conducted to document efficacy and safety of a new treatment before it can be approved by the regulatory authorities. […]

Henrik Toft Sørensen, Professor of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, is receiving the 2023 prize, accompanied by 1.5 million DKK. He receives the Prize in recognition of his major contribution to epidemiological research in Denmark and internationally, describes Novo Nordisk Foundation in a press release. In 2000, Henrik Toft Sørensen established the […]